Whether the first 48 h are decisive for the tumor-to-kidney dose ratio may, however, be questioned, given the fact that PSMA radioligands are effectively cleared via kidneys over time while the activity accumulated in the tumor is well retained over time. This evidence concerns the gene FOLH1 and neoplasm.